TRACON Pharmaceuticals (TCON) Reaches $2.15 After 3.00% Down Move; ARC Group WorldWide (ARCW) Covered By 2 Bullish Analysts Last Week

August 23, 2017 - By Nellie Frank

The stock of TRACON Pharmaceuticals Inc (NASDAQ:TCON) is a huge mover today! It is 0.00% or $0 reaching $2.15 per share. It is up 52.06% since August 23, 2016 and is downtrending. It has underperformed by 68.76% the S&P500.The move comes after 7 months negative chart setup for the $35.81 million company. It was reported on Aug, 23 by Barchart.com. We have $2.09 PT which if reached, will make NASDAQ:TCON worth $1.07M less.

Among 3 analysts covering ARC Group World Wide (NASDAQ:ARCW), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. ARC Group World Wide had 8 analyst reports since September 17, 2015 according to SRatingsIntel. Imperial Capital downgraded the shares of ARCW in report on Thursday, September 24 to “In-Line” rating. Imperial Capital maintained the shares of ARCW in report on Tuesday, November 15 with “In-Line” rating. The rating was maintained by Imperial Capital on Tuesday, September 27 with “In-Line”. The rating was maintained by Imperial Capital with “In-Line” on Thursday, February 11. See ARC Group WorldWide Inc (NASDAQ:ARCW) latest ratings:

12/04/2017 Broker: Imperial Capital Old Rating: In-Line New Rating: In-Line Old Target: $4.50 Removes

Among 4 analysts covering Tracon Pharmaceuticals Inc (NASDAQ:TCON), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Tracon Pharmaceuticals Inc has $18 highest and $10 lowest target. $15.33’s average target is 613.02% above currents $2.15 stock price. Tracon Pharmaceuticals Inc had 4 analyst reports since July 29, 2015 according to SRatingsIntel. Zacks upgraded the shares of TCON in report on Friday, September 4 to “Hold” rating. TH Capital initiated the stock with “Buy” rating in Wednesday, July 29 report. The stock has “Buy” rating by Jefferies on Wednesday, December 21. Roth Capital initiated the shares of TCON in report on Wednesday, July 29 with “Buy” rating.

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $35.81 million. The Firm is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases. It currently has negative earnings. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring).

ARC Group Worldwide, Inc. is a manufacturing company. The company has market cap of $40.89 million. The Firm has four divisions: Precision Components Group, 3DMT Group, Flanges and Fittings Group, and Wireless Group. It currently has negative earnings. It provides a set of manufacturing solutions, from design and prototyping through production.

About 33,144 shares traded or 103.45% up from the average. ARC Group WorldWide Inc (NASDAQ:ARCW) has risen 55.94% since August 23, 2016 and is uptrending. It has outperformed by 39.24% the S&P500.